Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.95
23.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Other Current Liabilities
Jiangsu Kanion Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
|
Other Current Liabilities
¥277.8m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-3%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Liabilities
¥530.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Current Liabilities
¥299.9m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
10%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Liabilities
¥3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Liabilities
¥3.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Liabilities
¥101.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jiangsu Kanion Pharmaceutical Co Ltd
Glance View
In the bustling landscape of the Chinese pharmaceutical industry, Jiangsu Kanion Pharmaceutical Co Ltd emerges as a pivotal player, seamlessly blending centuries-old traditional Chinese medicine (TCM) with cutting-edge modern technology. Founded in 1975, the company has carved a niche for itself by focusing on the research, development, and production of both TCM and integrated Western medicine. Kanion is renowned for its innovative approach, transforming ancient herbal remedies into scientifically-backed therapeutic solutions. The company's approach is not just about preserving tradition but rather enhancing it, ensuring that products meet rigorous modern medical standards, thereby appealing to a broad spectrum of healthcare needs. Kanion generates revenue through a diversified portfolio spanning herbal medicines, biochemical drugs, and health supplements. By implementing modern R&D methodologies, the company supports its vast array of products with robust clinical research, catering to both domestic and international markets. One of their key revenue streams is prescription medicines sold in hospitals and clinics, complemented by over-the-counter products available in pharmacies. Additionally, Kanion's investment in strategic partnerships and technological advancements has opened pathways for export, further amplifying its financial success. Through this blend of tradition and innovation, Jiangsu Kanion Pharmaceutical Co Ltd has established a resilient business model that thrives on the growing global acceptance of combining Eastern and Western medicinal practices.
See Also
What is Jiangsu Kanion Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
277.8m
CNY
Based on the financial report for Sep 30, 2024, Jiangsu Kanion Pharmaceutical Co Ltd's Other Current Liabilities amounts to 277.8m CNY.
What is Jiangsu Kanion Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-3%
Over the last year, the Other Current Liabilities growth was -77%. The average annual Other Current Liabilities growth rates for Jiangsu Kanion Pharmaceutical Co Ltd have been -27% over the past three years , -21% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
